These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 25245374)
1. p38 MAPK: a potential target of chronic pain. Lin X; Wang M; Zhang J; Xu R Curr Med Chem; 2014; 21(38):4405-18. PubMed ID: 25245374 [TBL] [Abstract][Full Text] [Related]
2. Novel strategies for inhibition of the p38 MAPK pathway. Zhang J; Shen B; Lin A Trends Pharmacol Sci; 2007 Jun; 28(6):286-95. PubMed ID: 17482683 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic Significance of p38 Isoforms (p38α, p38β, p38γ, p38δ) in Head and Neck Squamous Cell Carcinoma: Comparative Serum Level Evaluation and Design of Novel Peptide Inhibitor Targeting the Same. Sahu V; Nigam L; Agnihotri V; Gupta A; Shekhar S; Subbarao N; Bhaskar S; Dey S Cancer Res Treat; 2019 Jan; 51(1):313-325. PubMed ID: 29747487 [TBL] [Abstract][Full Text] [Related]
4. Comparative chemical array screening for p38γ/δ MAPK inhibitors using a single gatekeeper residue difference between p38α/β and p38γ/δ. Kondoh Y; Honda K; Hiranuma S; Hayashi T; Shimizu T; Watanabe N; Osada H Sci Rep; 2016 Jul; 6():29881. PubMed ID: 27431267 [TBL] [Abstract][Full Text] [Related]
5. p38 MAP kinase inhibitors as anti inflammatory agents. Amir M; Somakala K; Ali S Mini Rev Med Chem; 2013 Dec; 13(14):2082-96. PubMed ID: 24107108 [TBL] [Abstract][Full Text] [Related]
6. Downregulation of human endothelial nitric oxide synthase promoter activity by p38 mitogen-activated protein kinase activation. Xing F; Jiang Y; Liu J; Zhao K; Mo Y; Liu Z; Zeng Y Biochem Cell Biol; 2006 Oct; 84(5):780-8. PubMed ID: 17167542 [TBL] [Abstract][Full Text] [Related]
7. The Role of p38 MAPK in the Development of Diabetic Cardiomyopathy. Wang S; Ding L; Ji H; Xu Z; Liu Q; Zheng Y Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27376265 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. Mbalaviele G; Anderson G; Jones A; De Ciechi P; Settle S; Mnich S; Thiede M; Abu-Amer Y; Portanova J; Monahan J J Pharmacol Exp Ther; 2006 Jun; 317(3):1044-53. PubMed ID: 16501068 [TBL] [Abstract][Full Text] [Related]
9. Efficient adult skeletal muscle regeneration in mice deficient in p38beta, p38gamma and p38delta MAP kinases. Ruiz-Bonilla V; Perdiguero E; Gresh L; Serrano AL; Zamora M; Sousa-Victor P; Jardí M; Wagner EF; Muñoz-Cánoves P Cell Cycle; 2008 Jul; 7(14):2208-14. PubMed ID: 18641461 [TBL] [Abstract][Full Text] [Related]
10. p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Junttila MR; Ala-Aho R; Jokilehto T; Peltonen J; Kallajoki M; Grenman R; Jaakkola P; Westermarck J; Kähäri VM Oncogene; 2007 Aug; 26(36):5267-79. PubMed ID: 17334397 [TBL] [Abstract][Full Text] [Related]
11. p38 MAPK inhibition in nucleus pulposus cells: a potential target for treating intervertebral disc degeneration. Studer RK; Aboka AM; Gilbertson LG; Georgescu H; Sowa G; Vo N; Kang JD Spine (Phila Pa 1976); 2007 Dec; 32(25):2827-33. PubMed ID: 18246004 [TBL] [Abstract][Full Text] [Related]
12. Selective activation and functional significance of p38alpha mitogen-activated protein kinase in lipopolysaccharide-stimulated neutrophils. Nick JA; Avdi NJ; Young SK; Lehman LA; McDonald PP; Frasch SC; Billstrom MA; Henson PM; Johnson GL; Worthen GS J Clin Invest; 1999 Mar; 103(6):851-8. PubMed ID: 10079106 [TBL] [Abstract][Full Text] [Related]
13. The p38 MAPK inhibitors for the treatment of inflammatory diseases and cancer. Yong HY; Koh MS; Moon A Expert Opin Investig Drugs; 2009 Dec; 18(12):1893-905. PubMed ID: 19852565 [TBL] [Abstract][Full Text] [Related]
14. Molecular modeling of p38α mitogen-activated protein kinase inhibitors through 3D-QSAR and molecular dynamics simulations. Chang HW; Chung FS; Yang CN J Chem Inf Model; 2013 Jul; 53(7):1775-86. PubMed ID: 23808966 [TBL] [Abstract][Full Text] [Related]
15. Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity. Hill RJ; Dabbagh K; Phippard D; Li C; Suttmann RT; Welch M; Papp E; Song KW; Chang KC; Leaffer D; Kim YN; Roberts RT; Zabka TS; Aud D; Dal Porto J; Manning AM; Peng SL; Goldstein DM; Wong BR J Pharmacol Exp Ther; 2008 Dec; 327(3):610-9. PubMed ID: 18776065 [TBL] [Abstract][Full Text] [Related]
16. Protein kinases as targets for developing anticancer agents from marine organisms. Qiao G; Bi K; Liu J; Cao S; Liu M; Pešić M; Lin X Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129759. PubMed ID: 33038451 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of TRAIL-induced apoptosis by IL-8 is mediated by the p38-MAPK pathway in OVCAR3 cells. Abdollahi T; Robertson NM; Abdollahi A; Litwack G Apoptosis; 2005 Dec; 10(6):1383-93. PubMed ID: 16215677 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of p38 mitogen-activated protein kinase activation in the rostral anterior cingulate cortex attenuates pain-related negative emotion in rats. Cao H; Zang KK; Han M; Zhao ZQ; Wu GC; Zhang YQ Brain Res Bull; 2014 Aug; 107():79-88. PubMed ID: 25038392 [TBL] [Abstract][Full Text] [Related]
19. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor. Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108 [TBL] [Abstract][Full Text] [Related]
20. p38 MAP kinase inhibitors: many are made, but few are chosen. Dominguez C; Powers DA; Tamayo N Curr Opin Drug Discov Devel; 2005 Jul; 8(4):421-30. PubMed ID: 16022178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]